J&J pays $2.2B upfront for Ollin, taps Blackstone to fund eye disease trial
Johnson & Johnson is buying ophthalmology biotech Ollin Biosciences and its late-stage bispecific antibody for $2.2 billion upfront. The acquisition…
Johnson & Johnson is buying ophthalmology biotech Ollin Biosciences and its late-stage bispecific antibody for $2.2 billion upfront. The acquisition…